Does anti-HBV therapy benefit the prognosis of HBV-related hepatocellular carcinoma following hepatectomy?

Abstract

The Hepatitis B virus (HBV) is an important etiological factor for hepatocarcinogenesis, because HBV DNA load and HBV reactivation are major risks that influence the long-term survival of hepatocellular carcinoma (HCC) patients who underwent hepatectomy and, thus, may cause postoperative liver function deterioration, tumor recurrence, and reduce patient's overall survival. However, anti-HBV therapy can suppress HBV replication, improve the remnant liver function, render patients better able to tolerate HCC treatments, and may even improve their prognosis. In this paper, an anti-HBV therapy that benefits the prognosis of HBV-related HCC following hepatectomy is reviewed.

• Authors: Liang-He Yu, Nan Li, Jie Shi, Wei-Xing Guo, Meng-Chao Wu, Shu-Qun Cheng
• Journal: Annals of surgical oncology (Ann Surg Oncol) Vol. 21 Issue 3 Pg. 1010-5 (Mar 2014) ISSN: 1534-4681 [Electronic] United States
• PMID: 24121884 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antiviral Agents

Topics

• Antiviral Agents (therapeutic use)
• Carcinoma, Hepatocellular (drug therapy, surgery, virology)
• Hepatectomy (mortality)
• Hepatitis B (drug therapy, virology)
• Hepatitis B virus (genetics)
• Humans
• Liver Neoplasms (drug therapy, surgery, virology)
• Prognosis
• Viral Load